One problem for Grail is that some lump it into the same category as other genomics stocks that focus on prenatal screening. This group has become increasingly crowded. However, Grail is different -- ...
Grail is a leader in the potentially enormous multi-cancer early detection (MCED) test market. The company could have a major catalyst on the way with the potential FDA approval of its Galleri test.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results